Infliximab, which is a monoclonal antibody to tumor necrosis factor alpha (TNFα), has become the mainstay therapeutic agent for treating moderate to severe pediatric inflammatory bowel disease (PIBD). The gene discussed is TNF; the disease is inflammatory bowel disease.